SMRT Corepressor Emerges as Master Regulator of Bile Acid Homeostasis Through Nuclear Receptor Control

Bile acids have long been viewed primarily as digestive detergents, molecules produced by the liver that emulsify dietary fats and shuttle them through the intestine for absorption. Over the past two decades, however, researchers have come to appreciate that these cholesterol-derived molecules are far more than detergents. They are signaling molecules, endocrine messengers that travel through the bloodstream and activate a family of nuclear receptors to regulate their own synthesis, control glucose and lipid metabolism, and shape the composition of the gut microbiome. A new review published in Experimental & Molecular Medicine now argues that at the heart of this regulatory network sits a transcriptional corepressor called SMRT, whose activity helps determine whether the genes governing bile acid production, transport, and detoxification are silenced or expressed. The work synthesizes evidence that SMRT, working in concert with nuclear receptors, orchestrates bile acid homeostasis with a precision that individual receptors alone cannot achieve.

Nuclear receptors are ligand-activated transcription factors that bind specific DNA sequences and switch target genes on or off in response to small molecules. Several members of this superfamily are central players in bile acid biology. The farnesoid X receptor, or FXR, is the canonical bile acid sensor, activated by chenodeoxycholic acid and related species, and it feeds back to suppress the enzyme CYP7A1, the rate-limiting step in classical bile acid synthesis, largely through induction of the repressive nuclear receptor SHP. The pregnane X receptor and the constitutive androstane receptor act as xenobiotic and bile acid sensors that induce detoxification and export pathways, protecting hepatocytes from bile acid overload. The liver X receptor links oxysterol sensing to bile acid synthesis via CYP7A1 induction, while the retinoid X receptor serves as a common dimerization partner for many of these receptors. Each of these receptors, however, does not act alone: their output depends on the coregulatory proteins they recruit to DNA.

This is where SMRT enters the picture. SMRT, short for silencing mediator of retinoid and thyroid hormone receptors and also known as NCOR2, is one of the two major corepressors of the nuclear receptor superfamily, the other being its paralog NCoR1. In the absence of activating ligand, many nuclear receptors bind SMRT, which in turn recruits large multiprotein complexes containing histone deacetylases such as HDAC3, along with transducin beta-like proteins and other chromatin-modifying enzymes. These complexes deacetylate histones and maintain local chromatin in a transcriptionally repressive state. When ligand binds, the receptor undergoes a conformational change, releases the corepressor, and recruits coactivators instead. This ligand-dependent corepressor exchange is the fundamental switch that converts receptor binding into transcriptional activation, and it means that the abundance, localization, and post-translational modification state of SMRT directly shapes how strongly and how quickly target genes respond to their ligands.

For bile acid homeostasis specifically, SMRT has been implicated in the regulation of nearly every major nuclear receptor pathway in the hepatocyte and the enterocyte. In the FXR pathway, corepressor exchange at FXR target promoters such as SHP, BSEP, and the intestinal FGF15/FGF19 locus determines the strength of the enterohepatic feedback signal that restrains CYP7A1 expression. In the CAR and PXR pathways, SMRT occupancy at promoters of detoxification genes such as CYP2B and CYP3A, and at bile acid exporters, governs the inducible defense against cholestatic injury. In the LXR pathway, corepressor association with LXR/RXR heterodimers at the CYP7A1 promoter influences the balance between bile acid synthesis and cholesterol efflux. The review emphasizes that these are not independent circuits but an integrated network in which SMRT acts as a shared rheostat, tuning gene expression across pathways in response to nutritional state, circadian cues, and inflammatory signals.

The physiological consequences of disrupting this corepressor function are substantial. Animal studies over the past two decades have shown that perturbing corepressor complexes, particularly the SMRT- and NCoR-associated HDAC3 complex, produces profound metabolic phenotypes. Liver-specific deletion of HDAC3 in mice leads to marked alterations in lipid and bile acid metabolism, reflecting the loss of repressive chromatin marks at metabolic gene promoters. Similarly, mice with impaired corepressor recruitment to specific nuclear receptors display altered bile acid pool sizes, changes in the hydrophobicity of the bile acid pool, and altered sensitivity to cholestatic liver injury. Because bile acids themselves are cytotoxic at high concentrations and pro-carcinogenic when they accumulate in the intestine, the fidelity of this corepressor-mediated feedback is a matter of liver and gut health, not merely transcriptional housekeeping.

The review also highlights the emerging role of SMRT in the enterohepatic circulation itself. Bile acids are secreted into bile, stored in the gallbladder, released into the duodenum after meals, reabsorbed in the terminal ileum, and returned to the liver through portal blood. At each step, nuclear receptors in enterocytes and hepatocytes sense the local bile acid concentration and adjust transporter expression accordingly. SMRT-dependent repression and derepression at these transporter genes, including ASBT in the ileum and NTCP and BSEP in the liver, helps set the flux rate of the entire circulation. Disruption of this tuning can shift the bile acid pool toward more hydrophobic species, which are stronger FXR agonists but also more damaging to membranes, thereby creating a feedback loop that links corepressor function to both signaling intensity and cytotoxic risk.

Beyond classical bile acid metabolism, the review connects SMRT-regulated nuclear receptor signaling to systemic metabolic disease. Bile acids activate FXR and the membrane receptor TGR5 to influence glucose homeostasis, insulin sensitivity, thermogenesis in brown adipose tissue, and energy expenditure. The bile acid pool is also a major determinant of gut microbiome composition, and the microbiome in turn modifies bile acids through deconjugation and dehydroxylation, generating secondary bile acids with distinct receptor specificities. Because SMRT shapes the expression of the enzymes and transporters that determine which bile acids circulate and in what amounts, corepressor function sits upstream of this entire host-microbe metabolic axis. The authors argue that this positions SMRT as a potential node at which diet, microbiome, and nuclear receptor pharmacology converge, with implications for nonalcoholic fatty liver disease, cholestasis, metabolic syndrome, and gastrointestinal cancers.

Therapeutically, the framework has clear implications. FXR agonists such as obeticholic acid are already approved for certain cholestatic conditions and are being evaluated for metabolic liver disease, while dual and selective modulators of FXR, TGR5 agonists, and CAR activators are in various stages of development. The review suggests that the efficacy of such ligands depends not only on receptor binding but on the corepressor and coactivator landscape of the target tissue. A ligand that promotes efficient corepressor release will produce a stronger transcriptional response than one that does not, and tissue-specific differences in SMRT abundance could explain variable drug responses between patients and between liver and intestine. This perspective points toward a second generation of nuclear receptor therapeutics designed with coregulator exchange in mind, and toward biomarkers based on coregulator occupancy that could predict which patients will benefit from bile acid-directed therapies.

The review closes by identifying open questions that will define the next phase of the field. These include mapping the genome-wide occupancy of SMRT at bile acid-related loci in a cell-type-specific manner, determining how post-translational modifications of SMRT such as phosphorylation, ubiquitination, and sumoylation respond to nutritional and inflammatory signals, and clarifying how SMRT and NCoR1 divide labor between hepatocytes, cholangiocytes, and intestinal epithelial cells. Single-cell and chromatin profiling technologies are expected to accelerate this work, as are degrader and PROTAC approaches that can selectively manipulate corepressor complexes. What is already clear, the authors contend, is that bile acid homeostasis cannot be understood as a simple ligand-receptor-feedback circuit. It is a coregulator-dependent system in which SMRT provides the repressive counterweight that gives nuclear receptor signaling its dynamic range, its tissue specificity, and its resilience against metabolic and toxicological stress.

Subject of Research: SMRT corepressor regulation of nuclear receptor signaling in bile acid homeostasis

Article Title: SMRT regulation of nuclear receptors orchestrates bile acid homeostasis

Article References: Kim, K., Fang, S., Hong, S.-H., Cho, H., Leblanc, M., Jacinto, S., Schnabl, B., Atkins, A. R., Yu, R. T., Liddle, C., Truitt, M. L., Fan, W., Lee, C. M., Downes, M., & Evans, R. M. (2026). SMRT regulation of nuclear receptors orchestrates bile acid homeostasis. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01823-y

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01823-y

Keywords: SMRT, NCOR2, nuclear receptors, bile acids, FXR, CYP7A1, cholestasis, HDAC3, liver metabolism, enterohepatic circulation, corepressors, metabolic disease